1
Amy Ripka, Jeffrey Allen Campbell, Andrew Charles Good, Paul Michael Scola, Ny Sin, Brian Venables: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, May 9, 2006: US07041698 (59 worldwide citation)

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in t ...


2
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, December 26, 2006: US07153848 (56 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.


3
Paul Michael Scola, Fiona McPhee, Nicholas A Meanwell, Piyasena Hewawasam, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Warren K Volles, November 7, 2006: US07132504 (55 worldwide citation)

Compounds are disclosed having the general formula: wherein R1, R2, R3, R4, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


4
Paul Michael Scola, Jeffrey Allen Campbell, Ny Sin, Li Qiang Sun, Xiangdong Alan Wang: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, Warren K Volles, November 14, 2006: US07135462 (44 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein A, R2, R3, R′, B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


5
Carol Bachand, Makonen Belema, Daniel H Deon, Andrew C Good, Jason Goodrich, Clint A James, Rico Lavoie, Omar D Lopez, Alain Martel, Nicholas A Meanwell, Van N Nguyen, Jeffrey Lee Romine, Edward H Ruediger, Lawrence B Snyder, Denis R St Laurent, Fukang Yang, David R Langley, Lawrence G Hamann: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, February 9, 2010: US07659270 (43 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


6
Fiona McPhee, Jeffrey Allen Campbell, Stanley D Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J Carini, Barry L Johnson, Paul Michael Scola, Kenneth M Boy: Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus. Bristol Myers Squibb Company, Pamela A Mingo, February 6, 2007: US07173004 (43 worldwide citation)

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


7
Xiangdong Alan Wang, Li Qiang Sun, Sing Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Warren K Volles, Pamela A Mingo, November 11, 2008: US07449479 (42 worldwide citation)

Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


8
Thomas W Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P Bergstrom, Piyasena Hewawasam, Scott W Martin, Robert G Gentles: Inhibitors of HCV replication. Bristol Myers Squibb Company, James Epperson, Pamela A Mingo, March 25, 2008: US07348425 (38 worldwide citation)

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds


9
Carol Bachand, Makonen Belema, Daniel H Deon, Andrew C Good, Jason Goodrich, Clint A James, Rico Lavoie, Omar D Lopez, Alain Martel, Nicholas A Meanwell, Van N Nguyen, Jeffrey Lee Romine, Edward H Ruediger, Lawrence B Snyder, Denis R St Laurent, Fukang Yang, David R Langley, Gan Wang, Lawrence G Hamann: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, June 29, 2010: US07745636 (35 worldwide citation)

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.


10
Ny Sin, Andrew Charles Good, Brian Lee Venables, Paul Michael Scola, Nicholas A Meanwell: Hepatitis C virus inhibitors. Bristol Myers Squibb Company, Pamela A Mingo, January 29, 2008: US07323447 (34 worldwide citation)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for i ...